These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37005695)

  • 1. Protocol for a feasibility randomized controlled trial to evaluate the efficacy, safety and tolerability of N-acetylcysteine in reducing adverse drug reactions among adults treated for multidrug-resistant tuberculosis in Tanzania.
    Mpagama SG; Mvungi HC; Mbelele PM; Semvua HH; Liyoyo AA; de Guex KP; Sloan D; Kibiki GS; Boeree M; Phillips PPJ; Heysell SK
    Pilot Feasibility Stud; 2023 Apr; 9(1):55. PubMed ID: 37005695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
    Guglielmetti L; Ardizzoni E; Atger M; Baudin E; Berikova E; Bonnet M; Chang E; Cloez S; Coit JM; Cox V; de Jong BC; Delifer C; Do JM; Tozzi DDS; Ducher V; Ferlazzo G; Gouillou M; Khan A; Khan U; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moschioni M; O'Brien K; Okunbor O; Oyewusi L; Panda S; Patil SB; Phillips PPJ; Pichon L; Rupasinghe P; Rich ML; Saluhuddin N; Seung KJ; Tamirat M; Trippa L; Cellamare M; Velásquez GE; Wasserman S; Zimetbaum PJ; Varaine F; Mitnick CD
    Trials; 2021 Sep; 22(1):651. PubMed ID: 34563240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial.
    Patil SB; Tamirat M; Khazhidinov K; Ardizzoni E; Atger M; Austin A; Baudin E; Bekhit M; Bektasov S; Berikova E; Bonnet M; Caboclo R; Chaudhry M; Chavan V; Cloez S; Coit J; Coutisson S; Dakenova Z; De Jong BC; Delifer C; Demaisons S; Do JM; Dos Santos Tozzi D; Ducher V; Ferlazzo G; Gouillou M; Khan U; Kunda M; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moreau M; Moschioni M; Nahid P; Osso E; Oyewusi L; Panda S; Pâquet A; Thuong Huu P; Pichon L; Rich ML; Rupasinghe P; Salahuddin N; Sanchez Garavito E; Seung KJ; Velásquez GE; Vallet M; Varaine F; Yuya-Septoh FJ; Mitnick CD; Guglielmetti L
    Trials; 2023 Nov; 24(1):773. PubMed ID: 38037119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study protocol for safety and efficacy of all-oral shortened regimens for multidrug-resistant tuberculosis: a multicenter randomized withdrawal trial and a single-arm trial [SEAL-MDR].
    Fu L; Xiong J; Wang H; Zhang P; Yang Q; Cai Y; Wang W; Sun F; Zhang X; Wang Z; Chen X; Zhang W; Deng G
    BMC Infect Dis; 2023 Nov; 23(1):834. PubMed ID: 38012543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania.
    Mpagama SG; Heysell SK; Ndusilo ND; Kumburu HH; Lekule IA; Kisonga RM; Gratz J; Boeree MJ; Houpt ER; Kibiki GS
    PLoS One; 2013; 8(5):e62034. PubMed ID: 23675411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycobactericidal Effects of Different Regimens Measured by Molecular Bacterial Load Assay among People Treated for Multidrug-Resistant Tuberculosis in Tanzania.
    Mbelele PM; Mpolya EA; Sauli E; Mtafya B; Ntinginya NE; Addo KK; Kreppel K; Mfinanga S; Phillips PPJ; Gillespie SH; Heysell SK; Sabiiti W; Mpagama SG
    J Clin Microbiol; 2021 Mar; 59(4):. PubMed ID: 33536294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study).
    Esmail A; Oelofse S; Lombard C; Perumal R; Mbuthini L; Goolam Mahomed A; Variava E; Black J; Oluboyo P; Gwentshu N; Ngam E; Ackerman T; Marais L; Mottay L; Meier S; Pooran A; Tomasicchio M; Te Riele J; Derendinger B; Ndjeka N; Maartens G; Warren R; Martinson N; Dheda K
    Am J Respir Crit Care Med; 2022 May; 205(10):1214-1227. PubMed ID: 35175905
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparing adherence to MDR-TB treatment among patients on self-administered therapy and those on directly observed therapy: non-inferiority randomized controlled trial.
    Wekesa C; Sekaggya-Wiltshire C; Muyanja SZ; Lume I; Nabaggala MS; Parkes-Ratanshi R; Akello SA
    Trials; 2023 May; 24(1):326. PubMed ID: 37173761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
    Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
    BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial.
    Weng T; Sun F; Li Y; Chen J; Chen X; Li R; Ge S; Zhao Y; Zhang W
    BMC Infect Dis; 2021 Feb; 21(1):183. PubMed ID: 33596848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linezolid for drug-resistant pulmonary tuberculosis.
    Singh B; Cocker D; Ryan H; Sloan DJ
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012836. PubMed ID: 30893466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
    Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
    BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study to evaluate the hepatoprotective effect of N- acetylcysteine on anti tuberculosis drug induced hepatotoxicity and quality of life.
    Sukumaran D; Usharani P; Paramjyothi GK; Subbalaxmi MVS; Sireesha K; Abid Ali M
    Indian J Tuberc; 2023 Jul; 70(3):303-310. PubMed ID: 37562904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study.
    Dela AI; Tank NKD; Singh AP; Piparva KG
    Lung India; 2017; 34(6):522-526. PubMed ID: 29098997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.